Valeant launches hostile $53B bid for Allergan

Valeant Pharmaceuticals said Wednesday it has launched a tender offer for Allergan, the maker of Botox, taking its hostile bid directly to shareholders.

The cash and stock offer values Allergan Inc. at around $53 billion, and it expires Aug. 15.

Allergan said it will review the offer and said shareholders shouldn't take action on the right now.

Valeant, which is based in Canada, has teamed up with Bill Ackman's Pershing Square Capital Management to try to purchase Allergan. The two companies went public with their takeover attempt in April and have increased their original bid of about $45.6 billion several times.

Allergan, of Irvine, California, has said the latest offer is still too low.

Ackman—whose Pershing Square is Allergan's biggest —is also moving to replace most of Allergan's board.

On Tuesday Valeant Pharmaceuticals International Inc. said it planned to take a buyout offer directly to Allergan shareholders this week.

Allergan shares rose $1.74 to $162.27 in morning trading. Valeant stock added 13 cents to $119.

Related Stories

Valeant planning hostile bid for Allergan

date Jun 17, 2014

Valeant plans to take a buyout offer for Allergan directly to its shareholders this week, as the Botox maker continues to rebuff its proposals that have risen as high as $53 billion.

Recommended for you

Selecting the right tool for the job

date Apr 14, 2015

Randomized clinical trials of new drugs have long been considered the "gold standard" in determining safety and efficacy before drugs, biologics, vaccines or devices are introduced to the general public. However, in the case ...

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.